Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
WGS 
GeneDx Holdings Corp. (WGS)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: WGS (4-star) is a STRONG-BUY. BUY since 28 days. Simulated Profits (15.63%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $160.89
1 Year Target Price $160.89
| 5 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 663.07% | Avg. Invested days 38 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.59B USD | Price to earnings Ratio 1445.09 | 1Y Target Price 160.89 |
Price to earnings Ratio 1445.09 | 1Y Target Price 160.89 | ||
Volume (30-day avg) 6 | Beta 2.04 | 52 Weeks Range 55.17 - 170.87 | Updated Date 12/6/2025 |
52 Weeks Range 55.17 - 170.87 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.11 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-17 | When - | Estimate 0.386 | Actual 0.49 |
Profitability
Profit Margin 0.52% | Operating Margin (TTM) -2.79% |
Management Effectiveness
Return on Assets (TTM) 1.62% | Return on Equity (TTM) 0.84% |
Valuation
Trailing PE 1445.09 | Forward PE 238.1 | Enterprise Value 4552755626 | Price to Sales(TTM) 11.42 |
Enterprise Value 4552755626 | Price to Sales(TTM) 11.42 | ||
Enterprise Value to Revenue 11.32 | Enterprise Value to EBITDA 134.44 | Shares Outstanding 28904590 | Shares Floating 20700022 |
Shares Outstanding 28904590 | Shares Floating 20700022 | ||
Percent Insiders 12.27 | Percent Institutions 104.98 |
Upturn AI SWOT
GeneDx Holdings Corp.
Company Overview
History and Background
GeneDx Holdings Corp. was founded in 2000 and provides genetic testing services. It became a public company through a merger with CM Life Sciences II Inc., a special purpose acquisition company (SPAC), in 2022.
Core Business Areas
- Genetic Testing Services: GeneDx offers a wide array of genetic testing services including exome sequencing, whole genome sequencing and single gene testing to diagnose rare diseases and inherited conditions.
Leadership and Structure
The company is led by its CEO, Katherine Stueland. The organizational structure includes departments focused on research, development, operations, and commercial activities.
Top Products and Market Share
Key Offerings
- Exome Sequencing: Exome sequencing is a key offering used to identify genetic variants in coding regions of the genome. Competitors include Invitae (NVTA), Myriad Genetics (MYGN), and LabCorp (LH).
- Whole Genome Sequencing: Whole genome sequencing provides comprehensive analysis of the entire genome. Competitors include Illumina (ILMN), PacBio (PACB) and Complete Genomics.
- Single Gene Testing: Single gene testing is focused on identifying variants within a specific gene of interest. Competitors include Quest Diagnostics (DGX) and Eurofins Scientific.
Market Dynamics
Industry Overview
The genetic testing market is rapidly growing due to increasing awareness of genetic disorders, advancements in technology, and decreasing costs of sequencing. There is a growing trend towards personalized medicine.
Positioning
GeneDx is positioned as a leader in rare disease diagnostics. Competitive advantages include a large database of genetic variants and experienced team of geneticists and bioinformaticians.
Total Addressable Market (TAM)
The global genetic testing market is estimated to reach over $25 billion by 2028. GeneDx is positioned to capture a significant share of this market through its focus on rare disease diagnostics.
Upturn SWOT Analysis
Strengths
- Extensive genetic variant database
- Experienced team of geneticists and bioinformaticians
- Focus on rare disease diagnostics
- Wide range of genetic testing services
Weaknesses
- High operating costs
- Reliance on reimbursement from payers
- Limited profitability
- Competition from larger players
Opportunities
- Expansion into new geographic markets
- Development of new genetic tests
- Partnerships with pharmaceutical companies
- Increased adoption of personalized medicine
Threats
- Changes in reimbursement policies
- Increased competition
- Technological advancements by competitors
- Data security breaches
Competitors and Market Share
Key Competitors
- NVTA
- MYGN
- DGX
- ILMN
Competitive Landscape
GeneDx faces competition from larger, more established companies. It differentiates itself through its focus on rare disease diagnostics and extensive variant database.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data requires retrieving from official financial statements.
Future Projections: Future growth projections are best obtained from analyst reports.
Recent Initiatives: Recent initiatives can be derived from press releases and company announcements.
Summary
GeneDx is a company focused on rare disease diagnostics with a solid variant database. While its niche focus gives it an advantage, high operating costs and significant competition pose challenges. Future success relies on expanding into new markets and strategic partnerships. Maintaining data security and adapting to reimbursement changes are crucial.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GeneDx Holdings Corp.
Exchange NASDAQ | Headquaters Stamford, CT, United States | ||
IPO Launch date 2020-11-04 | President, CEO & Director Ms. Katherine A. Stueland | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1000 | Website https://www.genedx.com |
Full time employees 1000 | Website https://www.genedx.com | ||
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.